Omega-3 and Atopic Dermatitis: Does Supplementation Actually Help?

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition, usually starting in childhood, marked by dryness, itching, and characteristic erythematous-exudative lesions or lichenification depending on the phase and severity. The itch can be severe enough to disrupt sleep for both the child and the entire family, and the chronic nature of the disease means parents often look for additional, supportive ways to ease symptoms beyond standard topical treatment.

Omega-3 fatty acids, known above all for their beneficial effect on cardiovascular health, have for years also been studied for inflammatory skin conditions — their potential anti-inflammatory action, which we cover in more detail in our entry on omega-3, seems like a logical basis for the hypothesis that they might also ease the course of AD. Yet the evidence for this specific link has long been mixed, with some earlier studies showing no significant benefit.

In this article we examine what one of the newer, well-designed randomized trials on this topic found — and, just as importantly, exactly what product it tested, since that detail changes how the result should be interpreted.

A drop in SCORAD from 42 to 25 points is a clinically noticeable difference — SCORAD is a standard, widely used scale for assessing AD severity, accounting for the extent of lesions, their intensity, and subjective symptoms such as itching and sleep disturbance. Equally important is the drop in topical corticosteroid use, since limiting their long-term use is one of the meaningful practical goals of adjunctive AD treatment.

This is an important caveat for anyone who, based on this study, might consider buying plain fish oil (without GLA and vitamin D) expecting an identical effect. Vitamin D, for that matter, has its own separate line of research into its role in AD, which further complicates attributing the effect solely to omega-3 fatty acids.

Earlier literature on omega-3 fatty acids alone (without additional ingredients) in treating AD is, unlike the study described above, clearly inconsistent. Some smaller studies and open-label trials suggested improvement in skin lesion severity and itching, while others found no significant difference from placebo. This kind of discrepancy is common in supplement research on inflammatory skin conditions and usually stems from differences in dosage, intervention duration, participants' baseline disease severity, and sample size.

Omega-3 fatty acids, especially EPA and DHA, are precursors to anti-inflammatory compounds (including resolvins and protectins) that can compete with pro-inflammatory metabolites of arachidonic acid (an omega-6 fatty acid) for the same enzymatic pathways. In theory, this means sufficiently high omega-3 intake relative to omega-6 could shift the body's overall inflammatory profile toward a less pronounced inflammatory response — which would be beneficial in a disease like AD, which is underpinned by chronic skin inflammation.

It's worth remembering, though, that a convincing biochemical mechanism doesn't always translate into a clinically meaningful effect in practice — the human body regulates fatty acid metabolism at many levels, and supplementation alone doesn't necessarily shift the inflammatory profile enough to produce a noticeable improvement in skin symptoms for every patient.

Omega-3 in the context of AD is a topic where it's easy to jump to a shortcut — leaping from "a supplement containing omega-3 helped in a study" straight to "any fish oil will help any child with AD." An honest reading of this data means recognizing that the best-documented effect so far concerns a specific, combined mix of ingredients, tested in a relatively small group, not a universal prescription.